Iovance Biotherapeutics stock up 22.7% after insider buying

Iovance Biotherapeutics Inc IOVA shares were trading higher Monday after recent insider buying from Director Wayne Rothbaum.

What Happened: Rothbaum purchased 10 million shares of Iovance stock at an average price of $6.50 per share at the end of last week. The new buy brings his total position to more than 18 million shares.

Rothbaum bought shares of Iovance stock at a price from $5.98 to $6.31 per share, a move that came just days after several other company directors and executives picked up shares of the stock at a price that ranged from $5.98 to $6.31 per share.

Iovance is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to use a patient's immune system to eliminate cancer cells.

How much money can I put into iovance biotherapeutics? IOVA Price Action: Iovance has a 52 week high of $20.60 and a. The 52 week low was $5.42.

The stock was up 22.7% at $8.39 at the time of publication, according to Benzinga Pro.